Psychedelic studies in nonhuman primates: Past and future.
Jamie C. Masthay, Alex C. Kwan, Steve W. C. Chang
Molecular Psychiatry September 12, 2025 DOI: 10.1038/s41380-025-03240-5 (opens in new tab)
Study at a glance
AI-extracted from the abstract| Characteristics | Review Peer reviewed |
|---|---|
| Population | Nonhuman primates |
| Key findings | Psychedelics induce characteristic behavioral changes in nonhuman primates that mirror some human effects, including tolerance and low abuse liability, but evidence on visual hallucinations is mixed. |
Abstract
Studies of serotonergic or 'classic' psychedelics in nonhuman primates (NHPs) have provided valuable information about the drugs' effects on the brain and behavior in closely related species to humans. Psychedelics induce characteristic changes to both spontaneous and operant behaviors in NHPs, though variability exists in the different effects reported by different studies; this variability could be due to factors like differences across drugs, differences in dose ranges across studies, and inter-individual variability in drug responsiveness. Several effects of psychedelics in NHPs mirror those in humans, including development of tolerance to psychedelic effects and low abuse liability, though evidence is mixed on whether psychedelics cause visual hallucinations in NHPs. NHP studies have also examined psychedelic mechanisms of action, supporting and connecting existing findings from human and rodent studies. Here we review the knowledge gained from psychedelic research in NHPs encompassing multiple psychedelic compounds in several NHP species. We conclude by highlighting NHPs' potential to serve as preclinical models of psychedelic effects on psychiatric conditions and suggesting several directions for future research to ensure the accuracy and effectiveness of an NHP psychedelic model.
Citations in the library
Cites 86
- Psilocybin can occasion mystical-type experiences having substantial and sustained personal meaning and spiritual significance Psychopharmacology July 7, 2006
- Single-Dose Psilocybin for a Treatment-Resistant Episode of Major Depression. New England Journal of Medicine November 3, 2022
- Pilot study of the 5-HT2AR agonist psilocybin in the treatment of tobacco addiction Journal of Psychopharmacology September 11, 2014
- Neural correlates of the LSD experience revealed by multimodal neuroimaging. Proceedings of the National Academy of Sciences April 11, 2016
- Rapid antidepressant effects of the psychedelic ayahuasca in treatment-resistant depression: a randomized placebo-controlled trial Psychological Medicine June 15, 2018
and 81 more in the library